Reply to P. Gazzaniga et al.

Mohamed Bouchahda Raphael Saffroy Abdoulaye Karaboué Jocelyne Hamelin Pasquale Innominato Faouzi Saliba Nelly Bosselut Antoinette Lemoine Francis Lévi

JCO Precis Oncol

Mohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.

Published: November 2021